CellCura ASA ("CellCura") has over time worked intensely to identify and put in place a more viable long-term financing for the company. These efforts have not been successful and it has become clear that there is insufficient interest amongst the company's shareholders to initiate a new equity placement, or similar types of financing, for the company.

The Board of Directors has therefore today resolved to seek other alternatives for CellCura in order to secure the interests of the company and its shareholders. The Board of Directors will closely monitor this process and the financial situation of the company.

CellCura's CEO comments: "We regret to inform that despite our efforts for reducing costs and refocusing the Company, securing a basis for long-term financing has not been successful. The company cannot rely on shareholder loans as a long-term source of financing and the management has hence been asked to consider other ways of securing shareholder value. The financial situation is critical for the company."

Should the above initiative fail, it is unlikely that CellCura can continue its operations.

Oslo, 13 October 2014

CellCura ASA
Tore Viana-Rønningen
Chief Executive Officer
Phone: + 47 911 08 693

CellCura ASA is dedicated to the development and sales of cell technologies for use in assisted reproductive technology (ART) and stem cell research worldwide, representing improved safety and efficiency compared to traditional technology. CellCura is listed on the Oslo Axess market at the Oslo Stock Exchange (ticker: CELL)

www.cellcura.com

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)
distributed by